Andrew Victor Schally: Pioneering Neuroendocrinologist and Architect of Luteinizing Hormone-Releasing Hormone Analogs.

andrew schally biography historical vignette luteinizing hormone-releasing hormone prostate cancer

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Sep 2024
Historique:
accepted: 10 09 2024
medline: 14 10 2024
pubmed: 14 10 2024
entrez: 14 10 2024
Statut: epublish

Résumé

Andrew Victor Schally is a pioneering figure in endocrinology and neuroendocrinology, whose work has fundamentally transformed the understanding and treatment of hormone-related disorders and cancer. His research, particularly in the isolation, characterization, and clinical application of hypothalamic hormones, has been instrumental in advancing medical science. Schally's early life, marked by the adversities of World War II, shaped his resilience and determination, driving him to pursue a career in medical research. His groundbreaking discovery of luteinizing hormone-releasing hormone (LHRH) and its analogs revolutionized the treatment of hormone-dependent cancers, especially advanced prostate cancer, by providing an effective alternative to surgical castration. Beyond LHRH, Schally's contributions to the development of somatostatin analogs have also had a significant impact on the management of acromegaly and neuroendocrine tumors. This article reviews Schally's life and work, emphasizing his contributions to endocrinology, particularly in the context of LHRH and its clinical applications. The review outlines his early life and education, his pioneering research on hypothalamic hormones, and the development of LHRH analogs that have become a cornerstone in the treatment of prostate cancer. Schally's ability to translate basic scientific discoveries into practical therapeutic strategies has earned him numerous accolades, including the Nobel Prize in Physiology or Medicine in 1977. His legacy continues to inspire and guide research in endocrinology and oncology, underscoring the lasting impact of his scientific achievements.

Identifiants

pubmed: 39398731
doi: 10.7759/cureus.69137
pmc: PMC11467473
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e69137

Informations de copyright

Copyright © 2024, Grujić et al.

Déclaration de conflit d'intérêts

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Auteurs

Miloš Grujić (M)

Clinical Oncology, University of Kragujevac, Faculty of Medical Sciences, Kragujevac, SRB.

Marija Živković Radojević (M)

Clinical Oncology, University of Kragujevac, Faculty of Medical Sciences, Kragujevac, SRB.

Katarina Janković (K)

Clinical Oncology, University of Kragujevac, Faculty of Medical Sciences, Kragujevac, SRB.

Neda Milosavljević (N)

Clinical Oncology, University of Kragujevac, Faculty of Medical Sciences, Kragujevac, SRB.

Classifications MeSH